Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage

被引：45

作者：

Seiffge, David J. ^{[1
,2
,3
]}

Kagi, Georg ^{[4
]}

Michel, Patrik ^{[5
]}

Fischer, Urs ^{[6
]}

Bejot, Yannick ^{[7
]}

Wegener, Susanne ^{[8
]}

Zedde, Marialuisa ^{[9
]}

Turc, Guillaume ^{[10
]}

Cordonnier, Charlotte ^{[11
]}

Sandor, Peter S. ^{[12
]}

Rodier, Gilles ^{[13
]}

Zini, Andrea ^{[14
]}

Cappellari, Manuel ^{[15
]}

Schadelin, Sabine ^{[16
]}

Polymeris, Alexandros A. ^{[1
,2
,3
]}

Werring, David ^{[17
,18
]}

Thilemann, Sebastian ^{[1
,2
,3
]}

Maestrini, Ilaria ^{[11
]}

Berge, Eivind ^{[19
,20
]}

Traenka, Christopher ^{[1
,2
,3
]}

Vehoff, Jochen ^{[4
]}

De Marchis, Gian Marco ^{[1
,2
,3
]}

Kapauer, Monika ^{[4
]}

Peters, Nils ^{[1
,2
,3
,21
]}

Sirimarco, Gaia ^{[5
]}

Bonati, Leo H. ^{[1
,2
,3
]}

Arnold, Marcel ^{[6
]}

Lyrer, Philippe A. ^{[1
,2
,3
]}

De Maistre, Emmanuel ^{[22
]}

Luft, Andreas ^{[8
]}

Tsakiris, Dimtrios A. ^{[23
]}

Engelter, Stefan T. ^{[1
,2
,3
,21
]}

机构：

[1] Univ Hosp Basel, Stroke Ctr, Petersgraben 4, CH-4031 Basel, Switzerland

[2] Univ Basel, Petersgraben 4, CH-4031 Basel, Switzerland

[3] Univ Hosp, Dept Clin Res, Dept Neurol, Basel, Switzerland

[4] St Gallen Cantonal Hosp, Dept Neurol, St Gallen, Switzerland

[5] Univ Hosp, Dept Neurol, Lausanne, Switzerland

[6] Inselspital Bern, Dept Neurol, Bern, Switzerland

[7] Univ Hosp, Dept Neurol, Dijon Stroke Registry, Dijon, France

[8] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland

[9] New Santa Maria Hosp, Inst Hospitalizat & Sci Care, Neurol Unit, Stroke Unit, Reggio Emilia, Italy

[10] St Anne Hosp, Natl Inst Hlth & Med Res, Dept Neurol, U894, Paris, France

[11] Univ Lille, Lille Univ Hosp Ctr, Natl Inst Hlth & Med Res, U1171,Degenerat & Vasc Cognit Disorders,Dept Neur, Lille, France

[12] Baden Cantonal Hosp, Dept Neurol, Baden, Switzerland

[13] Annecy Genevois Hosp Ctr, Dept Neurol, Epagny Metz Tessy, France

[14] Modena Univ Hosp, SAgostino Estense Hosp, Dept Neurosci, Stroke Unit, Modena, Italy

[15] Integrated Univ Hosp, USD Stroke Unit, DAI Neurosci, Verona, Italy

[16] Univ Hosp Basel, Clin Trial Unit, Basel, Switzerland

[17] UCL, Dept Brain Repair & Rehabil, Ctr Stroke Res, Inst Neurol, London, England

[18] Natl Hosp Neurol & Neurosurg, London, England

[19] Oslo Univ Hosp, Dept Internal Med, Oslo, Norway

[20] Oslo Univ Hosp, Dept Cardiol, Oslo, Norway

[21] Univ Basel, Univ Ctr Med Aging & Rehabil Basel, Felix Platter Hosp, Neurorehabil Unit, Basel, Switzerland

[22] Univ Hosp, Hematol Lab, Dijon, France

[23] Univ Hosp Basel, Diagnost Hematol, Basel, Switzerland

来源：

ANNALS OF NEUROLOGY | 2018年 / 83卷 / 03期

关键词：

HEALTH-CARE PROFESSIONALS; INTRAVENOUS THROMBOLYSIS; ORAL ANTICOAGULANTS; IV THROMBOLYSIS; FACTOR XA; MANAGEMENT; GUIDELINES; COMPLICATIONS; REVERSAL;

D O I：

10.1002/ana.25165

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

ObjectiveInformation about rivaroxaban plasma level (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking rivaroxaban. MethodsIn a multicenter registry-based study (Novel Oral Anticoagulants in Stroke Patients collaboration; ClinicalTrials.gov: NCT02353585) of patients with stroke while taking rivaroxaban, we compared RivLev in patients with AIS and ICH. We determined how many AIS patients had RivLev100ng/ml, indicating possible eligibility for thrombolysis, and how many ICH patients had RivLev75ng/ml, making them possibly eligible for the use of specific reversal agents. We explored factors associated with RivLev (Spearman correlation, regression models) and studied the sensitivity and specificity of international normalized ratio (INR) thresholds to substitute RivLev using cross tables and receiver operating characteristic curves. ResultsAmong 241 patients (median age=80 years, interquartile range [IQR]=73-84; median time from onset to admission=2 hours, IQR=1-4.5 hours; median RivLev=89ng/ml, IQR=31-194), 190 had AIS and 51 had ICH. RivLev was similar in AIS patients (82ng/ml, IQR=30-202) and ICH patients (102ng/ml, IQR=51-165; p=0.24). Trough RivLev((137ng/ml)) occurred in 126/190 (66.3%) AIS and 34/51 (66.7%) ICH patients. Among AIS patients, 108/190 (56.8%) had RivLev100ng/ml. In ICH patients, 33/51 (64.7%) had RivLev75ng/ml. RivLev was associated with rivaroxaban dosage, and inversely with renal function and time since last intake (each p<0.05). INR1.0 had a specificity of 98.9% and a sensitivity of 25.7% to predict RivLev100ng/ml. INR1.4 had a sensitivity of 59.3% and specificity of 90.1% to predict RivLev75ng/ml. InterpretationRivLev did not differ between patients with AIS and ICH. Half of the patients with AIS under rivaroxaban had a RivLev low enough to consider thrombolysis. In ICH patients, two-thirds had a RivLev high enough to meet the eligibility for the use of a specific reversal agent. INR thresholds perform poorly to inform treatment decisions in individual patients. Ann Neurol 2018;83:451-459

引用

页码：451 / 459

页数：9

共 50 条

[21] Differences Between Anticoagulated Patients With Ischemic Stroke Versus Intracerebral Hemorrhage
Schaub, Fabian
Polymeris, Alexandros A.
Schaedelin, Sabine
Hert, Lisa
Meya, Louisa
Thilemann, Sebastian
Traenka, Christopher
Wagner, Benjamin
Seiffge, David
Gensicke, Henrik
De Marchis, Gian Marco
Bonati, Leo
Engelter, Stefan T.
Peters, Nils
Lyrer, Philippe
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (01):
[22] Direct Oral Anticoagulant Plasma Levels for the Management of Acute Ischemic Stroke
Marsch, Armin
Macha, Kosmas
Siedler, Gabriela
Breuer, Lorenz
Strasser, Erwin F.
Engelhorn, Tobias
Doerfler, Arnd
Schwab, Stefan
Kallmuenzer, Bernd
CEREBROVASCULAR DISEASES, 2019, 48 (1-2) : 17 - 25
[23] Acute Blood Pressure Management in Acute Ischemic Stroke and Spontaneous Cerebral Hemorrhage
McDermott, Mollie
Sozener, Cemal B.
CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2018, 20 (09)
[24] Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
Lee, Sang-Hwa
Kim, Beom Joon
Han, Moon-Ku
Park, Tai Hwan
Lee, Kyung Bok
Lee, Byung-Chul
Yu, Kyung-Ho
Oh, Mi Sun
Cha, Jae Kwan
Kim, Dae-Hyun
Nah, Hyun-Wook
Lee, Jun
Lee, Soo Joo
Ko, Youngchai
Kim, Jae Guk
Park, Jong-Moo
Kang, Kyusik
Cho, Yong-Jin
Hong, Keun-Sik
Choi, Jay Chol
Kim, Joon-Tae
Choi, Kangho
Kim, Dong-Eog
Ryu, Wi-Sun
Kim, Wook-Joo
Shin, Dong-Ick
Yeo, Minju
Lee, Juneyoung
Lee, Ji Sung
Gorelick, Philip B.
Bae, Hee-Joon
INTERNATIONAL JOURNAL OF STROKE, 2016, 11 (07) : 783 - 790
[25] Intracerebral Hemorrhage: A Common yet Disproportionately Deadly Stroke Subtype
O'Carroll, Cumara B.
Brown, Benjamin L.
Freeman, W. David
MAYO CLINIC PROCEEDINGS, 2021, 96 (06) : 1639 - 1654
[26] Does High Cerebral Microbleed Burden Increase the Risk of Intracerebral Hemorrhage After Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke?
Arca, Karissa N.
Demaerschalk, Bart M.
Almader-Douglas, Diana
Wingerchuk, Dean M.
O'Carroll, Cumara B.
NEUROLOGIST, 2019, 24 (01) : 40 - 43
[27] Prediction of intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke using multiple artificial neural networks
Dharmasaroja, Permphan
Dharmasaroja, Pornpatr A.
NEUROLOGICAL RESEARCH, 2012, 34 (02) : 120 - 128
[28] Increased microvascular permeability and low level of low-density lipoprotein cholesterol predict symptomatic intracerebral hemorrhage in acute ischemic stroke
Yuan, Tingting
Chen, Naifei
Jin, Hang
Yin, Hongmei
SCIENCE PROGRESS, 2020, 103 (02)
[29] Mechanical Thrombectomy in Patients with Acute Ischemic Stroke and Concomitant Intracranial Hemorrhage
Weller, Johannes M.
Meissner, Julius N.
Stoesser, Sebastian
Dorn, Franziska
Petzold, Gabor C.
Bode, Felix J.
CLINICAL NEURORADIOLOGY, 2022, 32 (03) : 809 - 816
[30] Pregnancy and acute ischemic stroke
Daniel, Ifj. Bereczki
ORVOSI HETILAP, 2016, 157 (20) : 763 - 766

← 1 2 3 4 5 →